Clinical Trial Update: TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports completion of a Phase 1/Phase 2 study evaluating TLK286 in combination with Doxil for platinum-refractory or resistant ovaria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• TLK286

Snippet

Sponsor: Telik | Conditions: Ovarian Neoplasms | Phase 1, Phase 2 | Status: COMPLETED